CD206 is a marker of tumor-promoting macrophages; in breast cancer, CD206+ macrophages contribute to tumor immunosuppression, angiogenesis, metastasis, and relapse.36–38 In contrast, bexarotene did not induce a change in the levels of CD206 in the tumors (Supplementary Fig. 2). Here, MRC1 is linked to breast carcinoma.